Associated Papers
Development and Verification of Virtual Population Models for Predicting Drug Pharmacokinetics in Ethnic North American Populations.
Ezuruike U et al.
Cpt: Pharmacometrics & Systems Pharmacology, 2025
Ethnogeographic and inter-individual variability of human ABC transporters.
Xiao Q et al.
Human Genetics, 2020
Establishment of the experimental procedure for prediction of conjugation capacity in mutant UGT1A1.
Takaoka Y et al.
Plos One, 2019
The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection.
Muscat AM et al.
Oncotarget, 2018
Effect of genetic variants of bilirubin metabolism on the degree of hyperbilirubinemia in African-American newborns.
Schutzman DL et al.
Journal of Perinatology : Official Journal of the California Perinatal Association, 2017
UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.
Yoshihama T et al.
Japanese Journal of Clinical Oncology, 2017
UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.
Takano M et al.
Pharmacogenomics and Personalized Medicine, 2017
Genetic modulators of sickle cell disease in French Guiana: Markers of the slave trade.
Simonnet C et al.
American Journal of Human Biology : the Official Journal of the Human Biology Council, 2016
Gly71Arg UGT1A1 polymorphism is associated with breast cancer susceptibility in Han Chinese women.
Shi J et al.
Genetics and Molecular Research : Gmr, 2016
Performance of In Silico Tools for the Evaluation of UGT1A1 Missense Variants.
Rodrigues C et al.
Human Mutation, 2015
UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.
Etienne-Grimaldi MC et al.
Fundamental & Clinical Pharmacology, 2015
[Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
Ma L et al.
Zhonghua Zhong Liu Za Zhi [chinese Journal of Oncology], 2015
Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
Yun F et al.
Journal of Cancer Research and Therapeutics, 2014
A probabilistic model to predict clinical phenotypic traits from genome sequencing.
Chen YC et al.
Plos Computational Biology, 2014
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia.
Shibata T et al.
International Journal of Clinical Oncology, 2014
Body fat percentage is a major determinant of total bilirubin independently of UGT1A1*28 polymorphism in young obese.
Belo L et al.
Plos One, 2014
Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.
Li M et al.
Oncotargets and Therapy, 2014
Distribution of selected gene polymorphisms of UGT1A1 in a Saudi population.
Alkharfy KM et al.
Archives of Medical Science : Ams, 2013
CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.
Chan SW et al.
European Journal of Clinical Pharmacology, 2013
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Inoue K et al.
The Tohoku Journal of Experimental Medicine, 2013
Comprehensive analysis of UGT1A1 genetic polymorphisms in Chinese Tibetan and Han populations.
Zhang X et al.
Biochemical Genetics, 2012
Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia.
Teh LK et al.
The Indian Journal of Medical Research, 2012
Is there diversity among UGT1A1 polymorphism in Japan?
Kobayashi M et al.
World Journal of Gastrointestinal Oncology, 2012
Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era.
Tzvetkov M et al.
Pathology, 2012
Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development.
Kurose K et al.
Drug Metabolism and Pharmacokinetics, 2012
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Sai K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
Neely M et al.
Antimicrobial Agents and Chemotherapy, 2010
Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans.
Man M et al.
Journal of Clinical Pharmacology, 2010
Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects.
Saito A et al.
Journal of Human Genetics, 2009
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.
Ribrag V et al.
Blood, 2009
Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.
Sugiyama E et al.
Drug Metabolism and Pharmacokinetics, 2009
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.
Zhang A et al.
The Pharmacogenomics Journal, 2007
Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
Nagar S et al.
Oncogene, 2006
Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American.
Kaniwa N et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005